Research programme: glaucoma therapies - Alcon/Vernalis
Alternative Names: Glaucoma therapies research programme - Alcon/VernalisLatest Information Update: 09 Apr 2021
At a glance
- Originator Alcon; Vernalis
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Glaucoma
Most Recent Events
- 09 Apr 2019 Novartis completed the spin-off of Alcon
- 10 Oct 2018 Vernalis has been acquired by Ligand Pharmaceuticals
- 17 Sep 2004 Discontinued - Preclinical for Glaucoma in United Kingdom (unspecified route)